Reports Q3 revenue $305.3M, consensus $300.47M. Chris Simon, Haemonetics’ CEO, stated: "Our strong performance continued in the third quarter despite the challenging macroeconomic environment. We are fueling our momentum and using it to invest in our Long-Range Plan, expanding our capital capacity and creating new opportunities to accelerate transformational growth and margin expansion."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HAE:
- Haemonetics 3rd Quarter Fiscal Year 2023 Earnings Release Available on Investor Relations Website
- Haemonetics price target raised to $110 from $100 at Mizuho
- ViewRay CFO to step down, William Burke to succeed
- Haemonetics management to meet virtually with JMP Securities
- Haemonetics management to meet with Mizuho